Literature DB >> 34014535

The Intricate Metabolism of Pancreatic Cancers.

Felipe Camelo1, Anne Le2,3.   

Abstract

Currently, approximately 95% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDAC), which are the most aggressive form and the fourth leading cause of cancer death with extremely poor prognosis [1]. Poor prognosis is primarily attributed to the late diagnosis of the disease when patients are no longer candidates for surgical resection [2]. Cancer cells are dependent on the oncogenes that allow them to proliferate limitlessly. Thus, targeting the expression of known oncogenes in pancreatic cancer has been shown to lead to more effective treatment [3]. This chapter discusses the complexity of metabolic features in pancreatic cancers. In order to comprehend the heterogeneous nature of cancer metabolism fully, we need to take into account the close relationship between cancer metabolism and genetics. Gene expression varies tremendously, not only among different types of cancers but also within the same type of cancer among different patients. Cancer metabolism heterogeneity is often prompted and perpetuated not only by mutations in oncogenes and tumor-suppressor genes but also by the innate diversity of the tumor microenvironment. Much effort has been focused on elucidating the genetic alterations that correlate with disease progression and treatment response [4, 5]. However, the precise mechanisms by which tumor metabolism contributes to cancer growth, survival, mobility, and aggressiveness represent a functional readout of tumor progression (Fig. 1).

Entities:  

Keywords:  Combined therapy; Glucose metabolism; Glutamine metabolism; KRAS mutation; Pancreatic ductal adenocarcinoma

Mesh:

Year:  2021        PMID: 34014535     DOI: 10.1007/978-3-030-65768-0_5

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  71 in total

Review 1.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

Review 2.  Oncogene addiction.

Authors:  I Bernard Weinstein; Andrew Joe
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

3.  Membrane properties of histaminergic tuberomammillary neurones of the rat hypothalamus in vitro.

Authors:  H L Haas; P B Reiner
Journal:  J Physiol       Date:  1988-05       Impact factor: 5.182

Review 4.  Roles for KRAS in pancreatic tumor development and progression.

Authors:  Marina Pasca di Magliano; Craig D Logsdon
Journal:  Gastroenterology       Date:  2013-06       Impact factor: 22.682

5.  Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming.

Authors:  Yoichiro Mitsuishi; Keiko Taguchi; Yukie Kawatani; Tatsuhiro Shibata; Toshihiro Nukiwa; Hiroyuki Aburatani; Masayuki Yamamoto; Hozumi Motohashi
Journal:  Cancer Cell       Date:  2012-07-10       Impact factor: 31.743

6.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

Review 7.  The complex landscape of pancreatic cancer metabolism.

Authors:  Cristovão Marques Sousa; Alec C Kimmelman
Journal:  Carcinogenesis       Date:  2014-04-17       Impact factor: 4.944

Review 8.  Dysregulated metabolism contributes to oncogenesis.

Authors:  Matthew D Hirschey; Ralph J DeBerardinis; Anna Mae E Diehl; Janice E Drew; Christian Frezza; Michelle F Green; Lee W Jones; Young H Ko; Anne Le; Michael A Lea; Jason W Locasale; Valter D Longo; Costas A Lyssiotis; Eoin McDonnell; Mahya Mehrmohamadi; Gregory Michelotti; Vinayak Muralidhar; Michael P Murphy; Peter L Pedersen; Brad Poore; Lizzia Raffaghello; Jeffrey C Rathmell; Sharanya Sivanand; Matthew G Vander Heiden; Kathryn E Wellen
Journal:  Semin Cancer Biol       Date:  2015-10-08       Impact factor: 15.707

9.  Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.

Authors:  Jaekyoung Son; Costas A Lyssiotis; Haoqiang Ying; Xiaoxu Wang; Sujun Hua; Matteo Ligorio; Rushika M Perera; Cristina R Ferrone; Edouard Mullarky; Ng Shyh-Chang; Ya'an Kang; Jason B Fleming; Nabeel Bardeesy; John M Asara; Marcia C Haigis; Ronald A DePinho; Lewis C Cantley; Alec C Kimmelman
Journal:  Nature       Date:  2013-03-27       Impact factor: 49.962

10.  Pancreatic cancers rely on a novel glutamine metabolism pathway to maintain redox balance.

Authors:  Costas A Lyssiotis; Jaekyoung Son; Lewis C Cantley; Alec C Kimmelman
Journal:  Cell Cycle       Date:  2013-06-10       Impact factor: 4.534

View more
  1 in total

1.  hnRNPA1/UP1 Unfolds KRAS G-Quadruplexes and Feeds a Regulatory Axis Controlling Gene Expression.

Authors:  Annalisa Ferino; Julien Marquevielle; Himanshi Choudhary; Giorgio Cinque; Coralie Robert; Anne Bourdoncle; Raffaella Picco; Jean-Louis Mergny; Gilmar F Salgado; Luigi E Xodo
Journal:  ACS Omega       Date:  2021-11-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.